13 exclusive Chinese patent medicines for cardiovascular and cerebrovascular diseases, eye-catching step length, Tasly...

Medical Network News on June 3 A few days ago, the National Bureau of Statistics released the results of the seventh national census, and the process of population aging has accelerated
.
Cardiovascular and cerebrovascular diseases are one of the common diseases of the elderly.
For a long time, Chinese patent medicines for cardiovascular and cerebrovascular diseases have been the largest treatment category in the terminal Chinese patent medicine market of public medical institutions in China
.
In 2020, the sales of 21 cardio-cerebrovascular Chinese patent medicines exceeded 1 billion yuan, of which 13 were exclusive products/formulations; 6 products had a growth rate of over 10%, and Ginkgo biloba extract injection exceeded 30%; there were 18 TOP20 brands The annual sales exceeded 1 billion yuan, and 3 brands were newly added to the list, with step length and Yiling etc.
eye-catching
.

 

Dominate the Chinese patent medicine market! The growth rate of cardio-cerebral vascular drugs outperforms the "market"

 

A few days ago, the National Bureau of Statistics released the results of the seventh national census, which mentioned that the population of 60 years old and above in mainland China is 260.
02 million people, accounting for 18.
70%, an increase of 5.
44 percentage points from 2010, showing that the proportion of the elderly population has increased rapidly.
, Aging has become the basic national condition of our country for a period of time to come
.

 

As one of the common diseases of the elderly, the prevalence of cardiovascular and cerebrovascular diseases has increased year by year in recent years
.
The "China Cardiovascular Health and Disease Report 2019" shows that the prevalence and mortality of cardiovascular diseases in China are still on the rise, and it is estimated that there are 330 million people suffering from cardiovascular diseases
.

 

　　According to the latest data from Minai.
com, affected by various factors such as policies and the epidemic, the market size of China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminal cardio-cerebral vascular patent medicines in 2020 There has been a decline, but the decline is smaller than the overall market for proprietary Chinese medicines
.
Cardiovascular and cerebrovascular Chinese patent medicines are the largest treatment category in the Chinese patent medicine market, accounting for more than 35% of the market share
.

 

　　Chinese patent medicines for cardiovascular and cerebrovascular diseases cover 4 therapeutic subcategories, focusing on cardiovascular disease drugs and cerebrovascular disease drugs.
The market share of cardiovascular disease drugs is increasing year by year
.

 

　　Competitive landscape of China's public medical institutions' terminal cardio-cerebral vascular Chinese patent medicines in 2020

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　The annual sales of 21 products exceed 1 billion, and 13 exclusive products are eye-catching

 

　　Cardiovascular and cerebrovascular Chinese patent medicine with terminal sales exceeding 1 billion yuan in China's public medical institutions in 2020

　　Note: with * is an exclusive product/dosage form

 

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　The sales of 21 proprietary Chinese medicines for cardiovascular and cerebrovascular diseases exceeded 1 billion yuan, with a total sales scale of more than 40 billion yuan; 21 products cover two therapeutic subcategories of cerebrovascular disease drugs and cardiovascular disease drugs, focusing on cardiovascular disease drugs (14 products ); Except for safflower yellow for injection and Rhodiola injection, the other 19 products are all products in the 2020 National Medical Insurance Catalogue
.

 

　　The growth rate of 6 products exceeded 10%, and 5 of them are exclusive products, including Tongxinluo capsules and Shensongyangxin capsules from Yiling Pharmaceutical, Shexiang Baoxin Pills from Shanghai Hutchison Pharmaceuticals, and Shuxiang from Mudanjiang Youbo Pharmaceuticals.
Xuetong injection, Yindan Xinnaotong soft capsule of Guizhou Bailing Enterprise Group; 11 product rankings rose, among which Ginkgo biloba extract injection rose 7 places, Shuxuetong injection rose 6 places, Xinluo Capsules and Shensong Yangxin Capsules both rose by 5 positions
.

 

　　The exclusive product Yindan Xinnaotong Soft Capsule of Guizhou Bailing Enterprise Group broke 1 billion yuan for the first time.
This product has the effects of promoting blood circulation and removing blood stasis, promoting qi and relieving pain, eliminating food and resolving stagnation.
It is used for chest pain caused by qi stagnation and blood stasis.
Chest pain, chest tightness, shortness of breath, heart palpitations, etc.
, are the 2020 National Medical Insurance Category B products and the 2018 basic drugs
.

 

　　Sales of Yindan Xinnaotong Soft Capsules in Public Medical Institutions in China (Unit: 100 million yuan)

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　Ginkgo biloba extract injection has soared by more than 30%.
The main manufacturers include Yuekang Pharmaceutical and Taiwan Jisheng Pharmaceutical Biotechnology.
Its main ingredient is Ginkgo biloba extract, which can improve the blood supply of the brain and peripheral blood vessels, and improve the blood supply.
To improve the role of circulation, in 2020, the sales of public medical institutions in China will exceed 2 billion yuan for the first time, an increase of 38.
58% year-on-year.
Among them, the market share of Yuekang Pharmaceutical is increasing year by year
.

 

　　Sales of Ginkgo biloba extract injection at terminal in China's public medical institutions (unit: 100 million yuan)

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　In terms of drug names, 13 of the 21 products are exclusive products (including exclusive dosage forms), of which Buchang Pharmaceuticals monopolizes 3, including Danhong Injection, Naoxintong Capsules and Wenxin Granules, and 2 of Yiling Pharmaceutical The products listed are Tongxinluo Capsules and Shensong Yangxin Capsules
.

 

　　Stride length, Yiling.
.
.
Leader, 18 brands over 1 billion were born

 

　　According to data from Meinenet.
com, in the competitive landscape of Chinese public medical institutions' terminal cardio-cerebral vascular Chinese patent medicine manufacturers in 2020, Buchang Pharmaceuticals takes the lead, with a market share of over 9%; Yiling Pharmaceutical has performed well, with a market share of over 5%; Wuzhou Pharmaceutical ( Group) and Shanghai Pharmaceutical's market share both exceeded 4%
.

 

　　Among the TOP20 brands, 18 brands have sales of more than 1 billion yuan.
Wuzhou Pharmaceutical (Group)'s Xueshuantong (freeze-dried) for injection leads the way; from the perspective of corporate brands, Buchang Pharmaceutical has 3 brands on the list, and Yiling Pharmaceutical There are 2 brands on the list
.

 

　　2020 China's public medical institutions' terminal cardiovascular and cerebrovascular Chinese patent medicines TOP10 brands

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　Three new brands are on the TOP20 list, namely Yindan Xinnaotong Soft Capsule of Guizhou Bailing Enterprise Group (%2011.
50%), Suxiaojiuxinwan (%2012.
63%) of Zhongxin Pharmaceutical's sixth Chinese medicine, and Ginkgo biloba of Yangzijiang Pharmaceutical Co.
, Ltd.
Leaf (%200.
13%)
.

 

　　Seven brands soared by more than 10%.
Among them, Yuekang Pharmaceutical's Ginkgo biloba extract injection soared by nearly 60%, and its ranking jumped from 19th in 2019 to 9th in 2020
.

 

　　Source: Mi Nei Net Database

　　Medical Network News on June 3 A few days ago, the National Bureau of Statistics released the results of the seventh national census, and the process of population aging has accelerated
.
Cardiovascular and cerebrovascular diseases are one of the common diseases of the elderly.
For a long time, Chinese patent medicines for cardiovascular and cerebrovascular diseases have been the largest treatment category in the terminal Chinese patent medicine market of public medical institutions in China
.
In 2020, the sales of 21 cardio-cerebrovascular Chinese patent medicines exceeded 1 billion yuan, of which 13 were exclusive products/formulations; 6 products had a growth rate of over 10%, and Ginkgo biloba extract injection exceeded 30%; there were 18 TOP20 brands The annual sales exceeded 1 billion yuan, and 3 brands were newly added to the list, with step length and Yiling etc.
eye-catching
.

 

　　Dominate the Chinese patent medicine market! The growth rate of cardio-cerebral vascular drugs outperforms the "market"

 

　　A few days ago, the National Bureau of Statistics released the results of the seventh national census, which mentioned that the population of 60 years old and above in mainland China is 260.
02 million people, accounting for 18.
70%, an increase of 5.
44 percentage points from 2010, showing that the proportion of the elderly population has increased rapidly.
, Aging has become the basic national condition of our country for a period of time to come
.

 

　　As one of the common diseases of the elderly, the prevalence of cardiovascular and cerebrovascular diseases has increased year by year in recent years
.
The "China Cardiovascular Health and Disease Report 2019" shows that the prevalence and mortality of cardiovascular diseases in China are still on the rise, and it is estimated that there are 330 million people suffering from cardiovascular diseases
.

 

　　According to the latest data from Minai.
com, affected by various factors such as policies and the epidemic, the market size of China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminal cardio-cerebral vascular patent medicines in 2020 There has been a decline, but the decline is smaller than the overall market for proprietary Chinese medicines
.
Cardiovascular and cerebrovascular Chinese patent medicines are the largest treatment category in the Chinese patent medicine market, accounting for more than 35% of the market share
.

 

　　Chinese patent medicines for cardiovascular and cerebrovascular diseases cover 4 therapeutic subcategories, focusing on cardiovascular disease drugs and cerebrovascular disease drugs.
The market share of cardiovascular disease drugs is increasing year by year
.

 

　　Competitive landscape of China's public medical institutions' terminal cardio-cerebral vascular Chinese patent medicines in 2020

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　The annual sales of 21 products exceed 1 billion, and 13 exclusive products are eye-catching

 

　　Cardiovascular and cerebrovascular Chinese patent medicine with terminal sales exceeding 1 billion yuan in China's public medical institutions in 2020

　　Note: with * is an exclusive product/dosage form

 

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　The sales of 21 proprietary Chinese medicines for cardiovascular and cerebrovascular diseases exceeded 1 billion yuan, with a total sales scale of more than 40 billion yuan; 21 products cover two therapeutic subcategories of cerebrovascular disease drugs and cardiovascular disease drugs, focusing on cardiovascular disease drugs (14 products ); Except for safflower yellow for injection and Rhodiola injection, the other 19 products are all products in the 2020 National Medical Insurance Catalogue
.

 

　　The growth rate of 6 products exceeded 10%, and 5 of them are exclusive products, including Tongxinluo capsules and Shensongyangxin capsules from Yiling Pharmaceutical, Shexiang Baoxin Pills from Shanghai Hutchison Pharmaceuticals, and Shuxiang from Mudanjiang Youbo Pharmaceuticals.
Xuetong injection, Yindan Xinnaotong soft capsule of Guizhou Bailing Enterprise Group; 11 product rankings rose, among which Ginkgo biloba extract injection rose 7 places, Shuxuetong injection rose 6 places, Xinluo Capsules and Shensong Yangxin Capsules both rose by 5 positions
.

 

　　The exclusive product Yindan Xinnaotong Soft Capsule of Guizhou Bailing Enterprise Group broke 1 billion yuan for the first time.
This product has the effects of promoting blood circulation and removing blood stasis, promoting qi and relieving pain, eliminating food and resolving stagnation.
It is used for chest pain caused by qi stagnation and blood stasis.
Chest pain, chest tightness, shortness of breath, heart palpitations, etc.
, are the 2020 National Medical Insurance Category B products and the 2018 basic drugs
.

 

　　Sales of Yindan Xinnaotong Soft Capsules in Public Medical Institutions in China (Unit: 100 million yuan)

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　Ginkgo biloba extract injection has soared by more than 30%.
The main manufacturers include Yuekang Pharmaceutical and Taiwan Jisheng Pharmaceutical Biotechnology.
Its main ingredient is Ginkgo biloba extract, which can improve the blood supply of the brain and peripheral blood vessels, and improve the blood supply.
To improve the role of circulation, in 2020, the sales of public medical institutions in China will exceed 2 billion yuan for the first time, an increase of 38.
58% year-on-year.
Among them, the market share of Yuekang Pharmaceutical is increasing year by year
.

 

　　Sales of Ginkgo biloba extract injection at terminal in China's public medical institutions (unit: 100 million yuan)

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　In terms of drug names, 13 of the 21 products are exclusive products (including exclusive dosage forms), of which Buchang Pharmaceuticals monopolizes 3, including Danhong Injection, Naoxintong Capsules and Wenxin Granules, and 2 of Yiling Pharmaceutical The products listed are Tongxinluo Capsules and Shensong Yangxin Capsules
.

 

　　Stride length, Yiling.
.
.
Leader, 18 brands over 1 billion were born

 

　　According to data from Meinenet.
com, in the competitive landscape of Chinese public medical institutions' terminal cardio-cerebral vascular Chinese patent medicine manufacturers in 2020, Buchang Pharmaceuticals takes the lead, with a market share of over 9%; Yiling Pharmaceutical has performed well, with a market share of over 5%; Wuzhou Pharmaceutical ( Group) and Shanghai Pharmaceutical's market share both exceeded 4%
.

 

　　Among the TOP20 brands, 18 brands have sales of more than 1 billion yuan.
Wuzhou Pharmaceutical (Group)'s Xueshuantong (freeze-dried) for injection leads the way; from the perspective of corporate brands, Buchang Pharmaceutical has 3 brands on the list, and Yiling Pharmaceutical There are 2 brands on the list
.

 

　　2020 China's public medical institutions' terminal cardiovascular and cerebrovascular Chinese patent medicines TOP10 brands

　　Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

 

　　Three new brands are on the TOP20 list, namely Yindan Xinnaotong Soft Capsule of Guizhou Bailing Enterprise Group (%2011.
50%), Suxiaojiuxinwan (%2012.
63%) of Zhongxin Pharmaceutical's sixth Chinese medicine, and Ginkgo biloba of Yangzijiang Pharmaceutical Co.
, Ltd.
Leaf (%200.
13%)
.

 

　　Seven brands soared by more than 10%.
Among them, Yuekang Pharmaceutical's Ginkgo biloba extract injection soared by nearly 60%, and its ranking jumped from 19th in 2019 to 9th in 2020
.

 

　　Source: Mi Nei Net Database